The secondary aim is to compare the two medication strategies to the control condition on changes in metabolic measures, including glucose, insulin, insulin resistance (measured as Quantitative Insulin Sensitivity Check Index; QUICKI and Homeostasis Model of Insulin Resistance; HOMA-IR [52,53]), triglycerides, total cholesterol, LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol, glucose and metabolic syndrome. This evidence concerns the gene INS and metabolic syndrome.